Tvardi Therapeutics, Inc. (TVRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $15.74M
Last updated: Nov 17, 2026 at 11:04 AM ET
Tvardi Therapeutics, Inc. (TVRD) Earnings: Report Dates and Results
Tvardi Therapeutics (TVRD) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Tvardi Therapeutics reported EPS of -$0.48, above the -$0.51 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TVRD has an expected report date of Mar 29, 2027.
Earnings History
Of the 33 quarters below that had an estimate, TVRD beat 8, missed 10 and matched 15. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 230.77% above the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.48 | -$0.51 | -$1.06 - -$0.28 | +5.88% | Beat | N/A | 8 | 2 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.69 | -$0.65 | -$0.78 - -$0.41 | -6.15% | Miss | -235.3% | 7 | 3 up, 1 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.73 | -$0.65 | -$0.79 - -$0.51 | -12.31% | Miss | N/A | 5 | 0 up, 2 down | May 8, 2026 | N/A |
| Dec 31, 2025 | -$0.78 | -$0.57 | -$0.65 - -$0.50 | -36.84% | Miss | N/A | 5 | 1 up, 0 down | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$0.59 | -$0.81 | N/A | +27.16% | Beat | N/A | 2 | N/A | Nov 13, 2025 | N/A |
| Jun 30, 2025 | $0.51 | -$0.39 | N/A | +230.77% | Beat | N/A | 2 | N/A | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.50 | -$0.58 | N/A | +13.79% | Beat | N/A | N/A | N/A | May 13, 2025 | N/A |
| Dec 31, 2024 | -$5.21 | -$0.20 | N/A | N/A | N/A | N/A | N/A | N/A | Feb 26, 2025 | N/A |
| Sep 30, 2024 | -$8.19 | -$8.64 | N/A | +5.26% | Beat | N/A | N/A | N/A | Nov 29, 2024 | N/A |
| Jun 30, 2024 | -$0.27 | -$0.26 | N/A | -3.85% | Miss | N/A | N/A | N/A | Aug 5, 2024 | N/A |
| Mar 31, 2024 | -$0.56 | -$0.40 | N/A | -40.00% | Miss | N/A | N/A | N/A | May 13, 2024 | $2.13M |
| Dec 31, 2023 | -$0.59 | -$0.45 | N/A | -31.11% | Miss | N/A | N/A | N/A | Mar 4, 2024 | $3.00M |
| Sep 30, 2023 | -$0.52 | -$0.52 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 13, 2023 | $4.87M |
| Jun 30, 2023 | -$0.58 | -$0.54 | N/A | -7.41% | Miss | N/A | N/A | N/A | Aug 7, 2023 | $6.93M |
| Mar 31, 2023 | -$0.49 | -$0.51 | N/A | +3.92% | Beat | N/A | N/A | N/A | May 15, 2023 | $6.17M |
| Dec 31, 2022 | -$0.56 | -$0.32 | N/A | -75.00% | Miss | N/A | N/A | N/A | Mar 6, 2023 | $3.26M |
| Sep 30, 2022 | -$0.43 | -$0.43 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 7, 2022 | $10.81M |
| Jun 30, 2022 | -$0.08 | -$0.08 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 8, 2022 | $23.00M |
| Mar 31, 2022 | -$0.52 | -$0.52 | N/A | 0.00% | In line | N/A | N/A | N/A | May 9, 2022 | $4.79M |
| Dec 31, 2021 | -$0.63 | -$0.63 | N/A | 0.00% | In line | -139.6% | N/A | N/A | Mar 1, 2022 | $821000 |
| Sep 30, 2021 | -$0.02 | -$0.02 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 8, 2021 | $20.27M |
| Jun 30, 2021 | -$0.61 | -$0.61 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 9, 2021 | N/A |
| Mar 31, 2021 | -$0.47 | -$0.47 | N/A | 0.00% | In line | N/A | N/A | N/A | May 10, 2021 | $1.94M |
| Dec 31, 2020 | $1.59 | $1.59 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 25, 2021 | $102.82M |
| Sep 30, 2020 | -$0.35 | -$0.35 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 9, 2020 | $18.53M |
| Jun 30, 2020 | -$0.54 | -$0.54 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 10, 2020 | $5.63M |
| Mar 31, 2020 | -$0.62 | -$0.62 | N/A | 0.00% | In line | N/A | N/A | N/A | May 11, 2020 | $8.09M |
| Dec 31, 2019 | -$0.61 | -$0.61 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 27, 2020 | $4.51M |
| Sep 30, 2019 | -$0.74 | -$0.74 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 5, 2019 | $5.79M |
| Jun 30, 2019 | -$0.58 | -$0.58 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 7, 2019 | $5.21M |
| Mar 31, 2019 | -$0.56 | -$0.58 | N/A | +3.45% | Beat | N/A | N/A | N/A | May 7, 2019 | $4.38M |
| Dec 31, 2018 | -$0.52 | -$0.58 | N/A | +10.34% | Beat | N/A | N/A | N/A | Mar 12, 2019 | $5.53M |
| Sep 30, 2018 | -$0.51 | -$0.49 | N/A | -4.08% | Miss | N/A | N/A | N/A | Nov 6, 2018 | $5.06M |
| Jun 30, 2018 | -$0.52 | -$0.51 | N/A | -1.96% | Miss | N/A | N/A | N/A | Aug 7, 2018 | $2.87M |
| Mar 31, 2018 | -$18.47 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 10, 2018 | N/A |
| Dec 31, 2017 | -$15.64 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 16, 2018 | N/A |
| Sep 30, 2017 | -$13.75 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 3, 2017 | N/A |
| Jun 30, 2017 | -$10.38 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 4, 2017 | N/A |
| Mar 31, 2017 | -$29.28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 5, 2017 | $911000 |
| Dec 31, 2016 | -$28.98 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 10, 2017 | N/A |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.36, after -$14.23 the year before. It was -$75.59 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.36 | N/A |
| Dec 31, 2024 | -$14.23 | N/A |
| Dec 31, 2023 | -$2.18 | N/A |
| Dec 31, 2022 | -$1.59 | N/A |
| Dec 31, 2021 | -$1.73 | -2262.5% |
| Dec 31, 2020 | $0.08 | N/A |
| Dec 31, 2019 | -$2.49 | N/A |
| Dec 31, 2018 | -$20.02 | N/A |
| Dec 31, 2017 | -$69.05 | N/A |
| Dec 31, 2016 | -$75.59 | N/A |
Frequently Asked Questions About TVRD
When is Tvardi Therapeutics's next earnings date?
Tvardi Therapeutics's next earnings report is expected for Mar 29, 2027.
Did TVRD beat earnings estimates last quarter?
Yes. Tvardi Therapeutics reported EPS of -$0.48 for the quarter ended Sep 30, 2026, above the -$0.51 estimate, a 5.88% surprise.
What EPS do analysts expect from TVRD next quarter?
The consensus EPS estimate for Tvardi Therapeutics for the quarter ending Dec 31, 2026 is -$0.43 from 11 analysts, with estimates from -$0.83 to -$0.14.
How often does TVRD beat earnings estimates?
Tvardi Therapeutics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +28.45%.
TVRD pages: Overview, Earnings, Forecast, Financials, Competitors